The Vanguard Group Discloses Stake in Avadel Pharmaceuticals

The Vanguard Group, Inc. has disclosed its position in Avadel Pharmaceuticals plc, as per Form 8.3 filed under Rule 8.3 of the Irish Takeover Panel Act, 1997. The filing dated October 27, 2025, reveals that Vanguard holds 5.67% of Avadel's US$0.01 ordinary shares, which equates to 5,524,858 shares. No derivatives or agreements to purchase or sell relevant securities were reported.

The disclosure also notes a minor transaction involving the sale of 190 shares at a unit price of 18.56 USD. There are no reported indemnity or option arrangements linked to these securities. Furthermore, no supplemental Form 8 was attached to detail positions on options or derivative transactions.

This stake disclosure is part of regulatory requirements after crossing the 1% ownership threshold. The document provides transparency on Vanguard’s interests in Avadel Pharmaceuticals, ensuring adherence to takeover rules.